US FDA approves three different oncology drugs in 1 week
.png)
In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications.
Since February 17, 2024 to the time of this article’s publication, the US FDA have announced approvals for three different oncology drug products from three different drugmakers: AstraZeneca, Iovance Biotherapeutics, and Johnson & Johnson. The approvals are as follows:
AstraZeneca
The US FDA has granted approval to AstraZeneca’s Tagrisso in combination with chemotherapy for the treatment of stage 3 EGFR-mutated non-small cell lung cancer (NSCLC). Tagrisso acts a targeted tyrosine kinase inhibitor, and has demonstrated a significant reduction in the risk of disease progression or death. For EGFR-mutated NSCLC, Tagrisso is currently the only targeted therapy to improve patient outcomes in both early- and late-stage disease. The FDA’s approval came based on trials that extended progression-free survival of a median of 9 years.
Executive Vice President of the Oncology Business Unit at AstraZeneca Dave Fredrickson stated in a press release: “This important new treatment option can delay disease progression by nearly 9 additional months, establishing a new benchmark with the longest reported progression-free survival benefit in the 1st-line advanced setting. This approval reinforces Tagrisso as the backbone of EGFR-mutated lung cancer treatment either as monotherapy or in combination with chemotherapy.”
While the clinical data for Tagrisso’s efficacy in reducing disease progression still requires maturation, a global study to assess Tagrisso’s efficacy and safety in combination with chemoradiation for stage III unresectable NSCLC in a phase III trial is estimated to be fully complete by 2026.
Iovance Biotherapeutics
Iovance Biotherapeutics was also granted accelerated approval by the US FDA for a cell therapy treatment for advanced melanoma, the first of its kind to be approved for the indication and for a solid tumour cancer.
AMTAGVI, a suspension for intravenous infusion, is a T cell immunotherapy for adult patients presenting with unresectable/metastatic melanoma that has been previously treated with a PD-1 blocking antibody. With accelerated approval based on the overall response rate and duration of response, AMTAGVI is currently undergoin phase III trials to confirm clinical significance.
Samantha R. Guild, President, AIM at the Melanoma Foundation, commented in a press release: “The approval of AMTAGVI offers hope to those with advanced melanoma who have progressed following initial standard of care therapies, as the current treatment options are not effective for many patients... This one-time cell therapy represents a promising innovation for the melanoma community, and we are excited by its potential to transform care for patients who are in dire need of additional therapeutic options.”
Johnson & Johnson
A bi-weekly treatment for those presenting with relapsed or refractory multiple myeloma has also been granted approval by the US FDA. TECVAYLI was granted FDA approval of the supplemental Biologics License Application at a reduced dosing frequency of 1.5 mg/kg every 2 weeks.
TECVAYLI is the first bispecific antibody targeting B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells, activating an immune response. In October 2022, TECVAYLI was approved for the treatment of adult patients with relapse/refractory multiple myeloma that had already received at least four lines of therapy.
Rachel Kobos, VP, Oncology Research & Development at Johnson & Johnson, stated in a press release: “TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today’s approval of bi-weekly dosing for eligible patients will further enable clinicians to meet the individual needs of patients who may want flexibility in their dosing schedules... As the first bispecific approved for the treatment of multiple myeloma, combined with the longest in-market experience by physicians, TECVAYLI is another example of our commitment to pioneering cutting-edge research to help improve outcomes for patients with multiple myeloma.”
Sources
[1] Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer [Accessed February 22, 2024] https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html
[2] Iovance’s AMTAGVI (Iifileucel) receives US FDA Accelerated Approval for Advanced Melanoma [Accessed February 22, 2024] https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvitm-lifileucel-receives-us-fda-accelerated
[3] TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the US FDA for the treatment of patients with relapsed or refractory multiple myeloma [Accessed February 22, 2024] https://investor.jnj.com/files/doc_news/2024/Feb/20/tecvayli-biweekly-dosing-fda-approval-press-release_final.pdf
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance